Interaction effects among IFN-γ+874, IL-2-330, IL-10-1082, IL-10-592 and IL-4-589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case–control study

Qiu-Ju Gao,1 Jia-Xin Xie,1 Li-Min Wang,1 Qiang Zhou,1 Shi-Yong Zhang2

ABSTRACT

Background The natural outcomes of hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections vary considerably among individuals. The infection may heal naturally, or patients may succumb to chronic liver diseases, including chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The mechanism is not fully understood.

Objectives To evaluate the interaction among four single nucleotide polymorphisms (SNPs) and their influence on different clinical outcomes.

Methods 277 individuals infected with HBV and/or HCV, including 81 patients with chronic hepatitis B and C, 122 asymptomatic HBV and/or HCV carriers and 74 controls who cleared HBV and HCV spontaneously, were involved in this study. The SNPs of four genes (rs2069762/−330 G/T of IL-2, rs2430561/+874 A/T of IFN-γ, rs1800872/−592 C/A of IL-10 and rs2234250/−589 C/A of IL-4) were analysed using restriction fragment length polymorphism-polymerase chain reaction or sequence-specific primer PCR. The gene–gene interactions were assessed using the multifactor-dimensionality reduction method.

Results Interleukin (IL)-10-592 AC and IL-4-589 CC/CT showed a synergistic effect on liver inflammatory injury (p<0.01), whereas interferon (IFN)-γ+874 AA and IL-2-330 TT had a synergistic impact (p<0.05). IFN-γ+874 AA and IL-10-1082 AA had an antagonistic effect (p<0.01) on the clinical progression, including asymptomatic HBV and HCV carriers and chronic hepatitis. IL-2-330 TT and IL-10-1082 AA synergistically influenced the clinical outcome (p<0.05). IFN-γ+874 AA, IL-2-330 TT and IL-10-1082 AA interactively affected the clinical outcome including asymptomatic HBV and HCV carriers and chronic hepatitis (p<0.05).

Conclusions Interactions among polymorphisms of IFN-γ+874 AA, IL-2-330 TT, IL-10-1082 AA, IL10--592 AC and IL-4-589 CC/CT significantly influenced the clinical progression of the subjects with HBV and/or HCV infection.

INTRODUCTION

The outcome of HBV and/or HCV infections varies considerably from person to person.1 2 Some individuals overcome the infection and are immune for the rest of their lives, whereas most people become disease carriers. Some carriers may have chronic liver diseases, such as chronic hepatitis (CH), liver cirrhosis and hepatocellular carcinoma.3 4 The mechanisms explaining these differences have not yet been determined. Evidence has shown that the different immune responses to the HBV/HCV infection in individuals result in different clinical outcomes.5 6

Helper T cells (Th) are known to play an important role in immunomodulation. The major cytokines, including interleukin 2 (IL-2) and interferon-gamma (IFN-γ), are secreted by Th1 cells. Th1 cytokines are...
associated with cell-mediated immunity to control intracellular pathogens, such as viruses, and participate in cytotoxic T lymphocyte proliferation and activation and activation of natural killer cells. The major lymphokines secreted by Th2 cells are interleukin 4 (IL-4) and interleukin 10 (IL-10). Th2 cytokines are essential for antibody-mediated immunity through proliferation and activation of the B lymphocytes. The cytokines from Th1 cells inhibit Th2 cells and vice versa. The imbalance of Th1 and Th2 disturbs the balance between the cell-mediated and antibody-mediated immunity, which might be the key factor in the clinical outcome of chronic HBV and HCV infections. Additionally, studies have shown that the different outcomes of patients with HBV and HCV infections are due to different levels of the Th1 and Th2 cytokines present. Many researchers have shown a correlation between the immunity level of the host and the relevant gene polymorphisms, especially single nucleotide polymorphisms (SNPs) in the promoter region that regulate the gene expression.

In our previous research, we reported that rs2069762/−330 G/T of IL-2, rs2430561/+874 A>T of IL-10, rs1800896/−1082 G>A and rs1800872/−592 C>A of IL-10 were strongly associated with the clinical outcome of subjects infected with HBV and/or HCV. However, the interleukins and SNPs of cytokines may not have independent roles, but may interact with each other in establishing the clinical significance. In this study, we analysed the effect of gene–gene interactions of rs2069762/−330 G/T of IL-2, rs2430561/+874 A>T of IL-10, rs1800896/−1082 G>A and rs1800872/−592 C>A of IL-10 and rs2243250/−589 C>T of IL-4 on the clinical outcomes of subjects with HBV and/or HCV infections using generalised multifactor-dimensionality reduction.

**METHODS**

**Study subjects**

Two hundred and seventy-seven people with HBV and/or HCV infection (137 male, 140 female), with a mean (SD) age of 50.2 (10.4) years (range 30–70 years), were included in the study. Of these, 81 patients were diagnosed with chronic hepatitis B (CHB) and/or chronic hepatitis C (CHC) (38 male, 43 female, mean (SD) age 49.8 (10.9) years), 122 patients were asymptomatic HBV and/or HCV carriers (ASC) (65 male, 57 female, mean (SD) age 51.3 (10.6) years) and 74 participants were controls who had been infected with HBV or HCV in the late 1980s because of plasma donation, but tested negative to HCV or HBV in 2007 (34 male, 40 female, mean (SD) age 48.6 (9.4) years). Subjects were classified into the following groups: (1) a control group; (2) asymptomatic hepatitis B surface antigen carriers and hepatitis C virus carriers, who fulfilled the following criteria: (i) seropositive for HBsAg and anti-HCV for at least 15 years, (ii) no evidence of liver cirrhosis based on the clinical criteria and ultrasound examination and (iii) normal alanine aminotransferase (ALT) (upper limit 80 U/L);

(3) patients diagnosed with chronic hepatitis B and/or hepatitis C, based on the following factors: (i) seropositive for HBsAg and anti-HCV for at least 15 years, (ii) serum HBV DNA positive and serum HCV RNA positive, (iii) persistent or intermittent elevation in ALT level and (iv) liver biopsy showing chronic hepatitis with moderate or severe necroinflammation. Patients who had other possible causes of hepatitis, including fatty liver and other concurrent illness, were excluded from this study. This study was approved by the ethics committees of the Centre for Disease Prevention and Control of Shijiazhuang and written consent was obtained from all voluntary subjects in accordance with the Declaration of Helsinki.

**Genotyping of SNPs**

Genomic DNA was extracted from the peripheral blood using a commercially available kit (Tiangen Biotech, Beijing, China). The genotype polymorphisms of rs2069762/−330 G/T of IL-2, rs2430561/+874 A>T of IL-10 and rs1800872/−592 C>A of IL-10 were examined using restriction fragment length polymorphism-polymerase chain reaction. The primer sequences, PCR reaction volume and conditions for restriction enzyme digestion were the same as reported in our previous study. The polymorphisms of rs1800896/−1082 G>A of IL-10 and rs2430561/+874 A>T of IL-4 were detected using the sequence-specific primer-PCR technique. The allele-specific primers, the PCR reaction volume and the internal control primers were used based on our previous publication.

**Statistical analysis**

Gene–gene interactions were analysed by multifactor-dimensionality reduction. The interaction between rs1800872/−592 C>A of IL-10 and rs2243250/−589 C>T of IL-4 and its relationship with abnormal ALT levels was evaluated. Similarly, the interactions among rs2430561/+874 A>T of IL-10, rs2069762/−330 G/T of IL-2 and rs1800896/−1082 G>A of IL-10, and their association with the clinical outcome were assessed. Appropriate models were used to test accuracy, cross-validation (CV) consistency and significance. The interaction indexes, including synergy index (S), attributable proportion of interaction (API) and relative excess risk of interaction (RERI) were evaluated based on the Rothman measures: (1) S = (RR11–1)/[(RR10–1)+(RR01–1)], (2) API = [RR11 (RR10 + RR01) +1]/ RR11, (3) RERI = RR11 * (RR10 + RR01) +1. The 95% CI of RERI was calculated by RERI(1±Z/√χ²). Frequencies of the genotypes among different groups were compared using the χ² test. The odds ratio (OR) and its 95% CI were also estimated. A p value of <0.05 was considered as statistically significant. All statistical tests were two sided.

**RESULTS**

Percentage homogeneity of patients infected with HCV, HBV combined HBV/HCV within each group

There were 37 cases (30.3%) of HCV infection, 43 (35.2%) of HBV infection and 42 (34.4%) of combined HBV and HCV infection. Results showed that of the genotypes among different groups were compared using the χ² test. The odds ratio (OR) and its 95% CI were also estimated. A p value of <0.05 was considered as statistically significant. All statistical tests were two sided.

Gao Q-J, et al. BMJ Open 2017;7:e013279. doi:10.1136/bmjopen-2016-013279
Table 1 The IL-10-592 and IL-4-589 genotypes and allele distribution of subjects with different alanine aminotransferase (ALT) levels

| Genotype and allele | <80 U/L (n=244) | ≥80 U/L (n=33) | χ² | p Value |
|---------------------|-----------------|----------------|-----|---------|
| IL-10-592 AA        | 110 (45.1)      | 8 (24.2)       | 6.32| <0.05   |
| CC                  | 27 (11.1)       | 3 (9.1)        |    |         |
| AC                  | 107 (43.9)      | 22 (66.7)      |    |         |
| A                   | 327 (67.0)      | 38 (57.6)      | 2.30| >0.05   |
| C                   | 161 (33.0)      | 28 (42.4)      |    |         |
| IL-4-589 CC         | 6 (2.5)         | 3 (9.1)        | 12.46| <0.05 |
| CT                  | 106 (43.4)      | 22 (66.7)      |    |         |
| TT                  | 132 (54.1)      | 8 (24.2)       |    |         |
| C                   | 118 (24.2)      | 28 (42.4)      | 9.97| <0.01   |
| T                   | 370 (75.8)      | 38 (57.6)      |    |         |

Table 2 The IL-2–330, IFN-γ+874 and IL-10–1082 genotypes and allele distribution of the subjects with different clinical outcomes

| Genotype and allele | Controls (n=74) | ASC (n=122) | CHB/C (n=81) | χ² | p |
|---------------------|-----------------|-------------|--------------|-----|---|
| IL-2–330 TT         | 22 (29.7)       | 54 (44.3)   | 23 (40.4)    | 13.46| <0.05|
| GG                  | 19 (25.7)       | 14 (11.4)   | 6 (10.5)     |    |   |
| TG                  | 33 (44.6)       | 54 (44.3)   | 28 (49.1)    |    |   |
| T                   | 77 (52.0)       | 163 (66.8)  | 74 (64.9)    | 11.69| <0.01|
| G                   | 71 (48.0)       | 81 (33.2)   | 40 (35.1)    |    |   |
| IFN-γ+874TT         | 8 (10.8)        | 14 (11.5)   | 5 (8.8)      | 14.8| <0.05|
| AA                  | 14 (18.9)       | 48 (39.3)   | 26 (45.6)    |    |   |
| TA                  | 52 (70.3)       | 60 (49.2)   | 26 (45.6)    |    |   |
| T                   | 68 (45.9)       | 90 (36.9)   | 36 (31.6)    | 5.68| <0.05|
| A                   | 80 (54.1)       | 154 (63.1)  | 78 (68.4)    |    |   |
| IL-10-1082GG        | 1 (1.4)         | 1 (0.8)     | 1 (1.8)      | 7.03| <0.05|
| AA                  | 16 (21.6)       | 44 (36.1)   | 24 (42.1)    |    |   |
| GA                  | 57 (77.0)       | 77 (63.1)   | 32 (56.1)    |    |   |
| G                   | 59 (39.9)       | 79 (32.4)   | 34 (29.8)    | 5.85| <0.05|
| A                   | 89 (60.1)       | 165 (67.6)  | 80 (70.2)    |    |   |

ASC, asymptomatic HBV and/or HCV carriers; HBV, hepatitis B virus; HCV, hepatitis C virus.

HCV infection in the ASC group, while in the group with CH, there were 18 cases (22.2%) of HCV infection, 36 cases (44.4%) of HBV infection and 27 (33.3%) patients with combined HBV/HCV infection. The population under study was therefore, shown to be homogeneous ($\chi^2=2.256$, p=0.324).

Genotype and allele distributions in the subjects with HBV and/or HCV infections

rs1800872/−592 C>A of IL-10 and rs2243250/−589 C>T of IL-4 correlated with abnormal ALT levels. While IL-10-592 AC showed an increased risk, IL-10-592 AA presented a reduced risk of unusual levels of ALT (OR (95% CI)=2.83 (1.21 to 6.63)). However, the IL-10–592 A/C alleles were not associated with such abnormal ALT levels (p>0.05). Although IL-4-589 CT/CC corresponded with an increased susceptibility, IL-4-589 TT showed a reduced risk of abnormal amounts of ALT [OR (95% CI)=3.43 (1.47 to 8.00) and 8.25 (1.74 to 39.22), respectively]. IL-4-589 C projected a higher risk; conversely, IL-4-589 T indicated a reduced possibility of a deviant ALT concentration (OR (95% CI)=2.31 (1.36 to 3.93)) (table 1).

rs2069762/−330 G/T of IL-2, rs2430561/+874 A>T of IFN-γ and rs1800896/−1082 G>A of IL-10 were observed to correlate with the clinical outcome. IL-2-330 TT/T, OR (95% CI)=3.33 (1.42 to 7.79)/1.86 (1.22 to 2.82); IFN-γ+874AA, OR (95% CI)=2.97 (1.47 to 5.99); and IL-10-1082 AA, OR (95% CI)=2.04 (1.05 to 3.97) were associated with an increased risk of ASC, CHB and CHC. In contrast, IL-2-330 GG/G, OR (95% CI)=3.31 (1.11 to 9.83)/1.71 (1.03 to 2.82); IFN-γ+874 TA, OR (95% CI)=3.71 (1.67 to 8.29); and IL-10-1082GA, OR (95% CI)=2.67 (1.24 to 5.75), were linked with a reduced risk of ASC, CHB and/or CHC (table 2).

Effect of gene–gene interaction and interaction indexes of IL-10-592 AC and IL-4-589 CC/CT on liver inflammatory injury

rs1800872/−592 C>A of IL-10 and rs2243250/−589 C>T of IL-4 revealed significant interactions with liver inflammatory injury in the subjects infected with HBV and/or HCV (p<0.01, testing accuracy=0.7112 and CV consistency=10/10) (table 3). IL-10-592 AC and IL-4-589 CC/
CT had a significant synergistic effect on the liver inflammatory injury, with a p value <0.01, OR (95% CI)=5.47 (1.93 to 15.49) and S=7.10. Among patients infected with HBV and/or HCV, the 67.6% of those who were in risk (as shown by the API score) of developing liver inflammatory injury was due to the interaction between IL-10-592 AC and IL-4-589 CC/CT genotypes. The extra risk of progression related to the interaction between these two genotypes was 3.70 times higher than that of other factors; RERI (95% CI)=3.70 (2.01 to 6.80) (table 4).

Impact of gene–gene interaction and interaction indexes of IFN-γ+874 AA, IL-2–330 TT and IL-10–1082 AA on the clinical outcomes of the subjects infected with HBV and HCV

rs2430561/+874 A>T of IFN-γ, rs2069762/−330 G/T of IL-2 and rs1800896/−1082 G>A of IL-10 showed a significant impact on the clinical outcomes of subjects infected with HBV and/or HCV (p<0.01). Testing accuracy and CV consistency of rs2430561/+874 A>T*rs2069762/−330 G/T were 0.6313 and 10/10, respectively; and that of rs2430561/+874 A>T*rs1800896/−1082 G>A were 0.6496 and 10/10, respectively. While rs2069762/−330 G/T*rs1800896/−1082 G>A presented a testing accuracy and CV consistency of 0.6182 and 10/10, respectively, the values for rs2430561/+874 A>T*rs1800896/−1082 G>A*rs2069762/−330 G/T were 0.5902 and 9/10, respectively (table 3).

IFN-γ+874 AA and IL-2–330 TT significantly progressed and had a synergistic effect on the clinical outcome of ASC or CH, with p<0.01; OR (95% CI)=10.13 (2.25 to 45.68) and 11.40 (2.40 to 54.22), respectively; and S=13.04 and 5.59, respectively (table 5). The clinical manifestation of ASC and CH with 83.2% and 74.9% risks (in terms of the API), respectively, were due to the interaction between IFN-γ+874 AA and IL-2-330 TT genotypes. The additional risk of the clinical outcome resulting from the interaction between the two genotypes was higher than due to other factors, as reflected by the RERI (95% CI)=8.43 (2.95 to 24.06) for ASC, 8.54 (2.97 to 24.53) for CH.

IFN-γ+874 AA and IL-10-1082 AA interactively impeded the progression of HBV and HCV infections to ASC and CH [OR (95% CI)=3.27 (1.10 to 9.72) and 5.97 (1.92 to 18.56), respectively; p<0.05] (table 5); and showed a significant antagonistic effect on these clinical outcomes in the subjects infected with HBV and/or HCV (S=0.47, 0.67, respectively). Furthermore, the protective actions could be attributed to the interaction between the genotypes, IFN-γ+874 AA and IL-10-1082 AA (API=−79.21%, −41.21%, respectively). Meanwhile, the excess protection resulting from the interaction was −2.59 (-1.80 to −3.73) and −2.46 (-1.74 to −3.47) times lower than due to other factors, as indicated by these RERI (95% CI) scores.

The IL-2–330 TT and IL-10–1082 AA had a significant and synergistic impact on the clinical developments to ASC and CH; p<0.05, OR (95% CI)=3.34 (1.24 to 9.01), 4.73 (1.66 to13.47), respectively, S=1.65, 1.40 (table 7). In the clinical outcome of the subjects as ASC and CH, 27.54% and 22.41% of the risks (as signified by the API scores) were due to the interaction between IL-2–330 TT and IL-10–1082 AA genotypes. Furthermore, the RERI scores indicated that the excess risk of this interaction results in the progression of the infection was 0.92 (0.88 to 0.96) and 1.06 (1.03 to 1.09), respectively.

IFN-γ+874 AA, IL-2-330 TT and IL-10-1082 AA presented certain associations with the clinical outcome, such as ASC or CH in patients infected with HBV and HCV; OR (95% CI)=9.60 (1.15 to 80.39), 17.23 (1.92 to 154.30), respectively, p<0.05 (table 7). However, no interactions developed into ASC, they progressed only to CH (S=1.06, 2.01 to6.80) (table 4).
higher than that of other factors. This result suggested that it might be worth exploring IL-10 and IL-4 to cure the liver inflammatory injury in patients with hepatitis with different genotypes of IL-10-592 AC and IL-4-589 CC/CT.

IL-2 has a powerful immunoregulatory effect on the stimulation of proliferation and activation of T lymphocytes, natural killer cells and B lymphocytes. IFN-\(\gamma\) plays an important role in modulating almost all the immune responses, including T cell differentiation, anti-proliferation, anti-tumour and antiviral activities. It shows that IFN-\(\gamma\)-874 AA genotype and IL-2-330 TT genotype interactively led to the progression of the HBV/HCV infections to ASC [OR (95% CI)=10.13 (2.25 to 45.68)] and CH [OR (95% CI)=11.40 (2.40 to 54.22)]. The risks of the subjects with these genotypes for developing ASC and CH were greater than the IFN-\(\gamma\)-874 AA genotype (6.80 and 4.87 times, respectively) and the IL-2-330 TT genotype (8.37 and 7.50 times, respectively). IFN-\(\gamma\)-874 AA genotype and IL-2-330 TT genotype showed significant synergy towards the clinical manifestation of ASC and CH (S=13.04, 5.59). Furthermore, Bei et al reported that the interaction between IL-2-330 and IFN-\(\gamma\)-1615 was associated with an increased risk of hepatocellular carcinoma (OR=1.078, 95% CI=1.022 to 1.136). In our study, the excess risk presented by the interaction between IFN-\(\gamma\)-874 AA and IL-2-330 TT for the clinical outcome suggested that it was worth investigating IFN-\(\gamma\) and IL-2 to provide a cure for patients with hepatitis with different genotypes of IFN-\(\gamma\)-874 AA and IL-2-330 TT. In a study by Wang et al, the concentrations of IL-2 and IFN-\(\gamma\) were found to be significantly elevated in the patients with CHB. IFN-\(\gamma\) levels increased significantly in the patients with CHC.

### Table 5

| IFN-\(\gamma\)-874 AA | IL-2-330 TT | Clinical outcome |
|---------------------|-------------|-----------------|
|                     | Control\(^1\) | ASC\(^2\) | p Value | OR (95% CI)\(^{2vs1}\) | CHB/C\(^3\) | p Value | OR (95% CI)\(^{2vs1}\) |
| -                   | -            | 38       | 45      | -         | 1.00     | 23      | 1.00     |
| +                   | -            | 13       | 23      | >0.05     | 1.49 (0.67 to 3.34) | 20      | =0.05    | 2.34 (1.00 to 5.54) |
| -                   | +            | 21       | 30      | >0.05     | 1.21 (0.60 to 2.44) | 21      | >0.05    | 1.52 (0.69 to 3.34) |
| +                   | +            | 2         | 24      | <0.01     | 10.13 (2.25 to 45.68) | 15      | <0.01    | 11.40 (2.40 to 54.22) |

\(^1\)Control; \(^2\)ASC; \(^3\)CHB/C:ASC, asymptomatic HBV and/or HCV carriers; HBV, hepatitis B virus; HCV, hepatitis C virus.

### Table 6

| IFN-\(\gamma\)-1082 AA | IL-10-1082 AA | Clinical outcome |
|---------------------|-------------|-----------------|
|                     | Control\(^1\) | ASC\(^2\) | p Value | OR (95% CI)\(^{2vs1}\) | CHB/C\(^3\) | p Value | OR (95% CI)\(^{2vs1}\) |
| -                   | -            | 49       | 45      | -         | 1.00     | 23      | 1.00     |
| +                   | -            | 9        | 33      | <0.01     | 3.99 (1.72 to 9.26) | 21      | <0.01    | 4.97 (1.97 to 12.53) |
| -                   | +            | 11       | 29      | <0.01     | 2.87 (1.29 to 6.41) | 23      | <0.01    | 4.46 (1.86 to 10.66) |
| +                   | +            | 5        | 15      | <0.05     | 3.27 (1.10 to 9.72) | 14      | <0.01    | 5.97 (1.92 to 18.56) |

\(^1\)Control; \(^2\)ASC; \(^3\)CHB/C:ASC, asymptomatic HBV and/or HCV carriers; HBV, hepatitis B virus; HCV, hepatitis C virus.
Table 7  Effect of the interaction of IL-2-330 TT and IL-10-1082 AA on the clinical outcome of the subjects with HBV/HCV (n)

| IL-2-330 TT | IL-10-1082 AA | Clinical outcome |
|-------------|---------------|-----------------|
|             | Control¹      | ASC²            | p Value | OR (95% CI)²⁻¹ | CHB/C³ | p Value | OR (95% CI)²⁻¹ |
| −           | −             | 41              | 47      | 1.00           | 26     | <0.05   | 1.00          |
| +           | −             | 17              | 31      | >0.05          | 18     | >0.05   | 1.67 (0.73 to 3.81) |
| −           | +             | 10              | 21      | >0.05          | 19     | <0.05   | 3.00 (1.21 to 7.44) |
| +           | +             | 6               | 23      | <0.05          | 18     | <0.01   | 4.73 (1.66 to 13.47) |

¹Control; ²ASC; ³CHB/C, asymptomatic HBV and/or HCV carriers; HBV, hepatitis B virus; HCV, hepatitis C virus.

In a study on the correlation between IL-10 and outcome of the HBV or HCV infections, Sofian et al.²⁷ reported a greater prevalence of IL-10-1082 GG in the group with persistent HBV. Similarly, da Silva et al.²⁸ detected higher frequencies of IL-10-1082 GG/G in patients infected with HCV and Akcam et al.²⁹ revealed that the frequency of IL-10 was significantly higher in the hepatitis B and C groups than in controls. In our study, IFN-γ+874 AA genotype and IL-10-1082 AA genotype interactively led to the progression of patients with HBV and/or HCV infections to asymptomatic HBV and/or HCV carriers and CH [OR (95% CI)=3.27 (1.10 to 9.72), 5.97 (1.92 to 18.56)]. Nevertheless, the SNPs of IFN-γ+874 AA and IL-10-1082 AA had a significant antagonistic effect on the clinical outcome of subjects (S=0.47, 0.67). The interaction of the IFN-γ+874 AA genotype and IL-10-1082 AA genotype offered excess protection, as indicated by the RERI scores (−2.59 and −2.46, respectively). Our data provided the evidence that IL-10 and IFN-γ are associated with the clinical outcome of the subjects infected with HBV and/or HCV,³⁰ ³¹ and offered a molecular basis for the antagonism between the Th1 and Th2 cytokines. Simultaneously, these findings indicated that IL-10 and IFN-γ could be combined and studied for the treatment of patients with different genotypes of IL-10-1082 AA and IFN-γ+874 AA.

Table 8  Effect of the interaction of IFN-γ+874 AA, IL-2-330 TT and IL-10-1082 AA genotypes on the clinical outcome of the subjects with HBV/HCV (n)

| IFN-γ+874 AA | IL-2-330 TT | IL-10-1082 AA | Clinical outcome |
|--------------|-------------|---------------|-----------------|
|              | Control¹    | ASC²          | p Value | OR (95% CI)²⁻¹ | CHB/C³ | p Value | OR (95% CI)²⁻¹ |
| −           | −           | 32            | 30      | 1              | 13     | −       | 1              |
| +           | −           | 6             | 15      | >0.05          | 2.67 (0.92 to 7.77) | 12     | <0.01   | 4.92 (1.52 to 15.91) |
| −           | +           | 9             | 17      | >0.05          | 2.02 (0.78 to 5.21) | 13     | <0.05   | 3.56 (1.22 to 10.33) |
| +           | +           | 15            | 17      | >0.05          | 1.21 (0.51 to 2.84) | 10     | >0.05   | 1.64 (0.59 to 4.59) |
| +           | +           | 2             | 14      | <0.01          | 7.47 (1.56 to 35.64) | 8      | <0.01   | 9.85 (1.84 to 52.74) |
| −           | +           | 5             | 14      | =0.05          | 2.99 (0.96 to 9.30) | 11     | <0.01   | 5.42 (1.57 to 18.68) |
| +           | −           | 4             | 6       | >0.05          | 1.60 (0.41 to 6.23) | 7      | <0.05   | 4.31 (1.08 to 17.25) |
| +           | +           | 1             | 9       | <0.05          | 9.60 (1.15 to 80.39) | 7      | <0.01   | 17.23 (1.92 to 154.30) |

¹Control; ²ASC; ³CHB/C, asymptomatic HBV and/or HCV carriers; HBV, hepatitis B virus; HCV, hepatitis C virus.
alone but depended on interactions among multiple factors. In this study, we found that IL-10-592 AC and IL-4-589 CC/CT had a synergistic effect on the liver inflammatory injury in the subjects. IFN-γ+874 AA and IL-2-330 TT synergistically affected the risk of clinical progression of HBV and/or HCV infections. In contrast, IFN-γ+874 AA and IL-10-1082 AA had noticeable antagonistic effects on the clinical outcome. IL-2-330 TT and IL-10-1082 AA displayed a weaker impact on the clinical outcome. The interactions among IFN-γ+874 AA, IL-2-330 TT and IL-10-1082 AA showed no influence on asymptomatic HBV and HCV carriers, but they had a weak synergistic effect on chronic hepatitis. These results suggest that different countermeasures for treatment should be investigated in patients with hepatitis with the genotypes IFN-γ+874 AA, IL-2-330 TT, IL-10-1082 AA, IL-10-592 AC and IL-4-589 CC/CT.

In this study, the size of the subgroups of individuals with HBV and/or HCV infections varied, which might have led to biases. More ideally, the samples should have been assessed by stratifying individuals into subgroups with individuals infected only by HCV and only by HBV. In addition, the correlation between interactions among the SNPs and the level of cytokines needs further investigation.

Contributors Q-JG designed the research, performed most of the experiments and drafted the manuscript; J-xX analysed the data and edited the paper; L-MW took the SNPs and the level of cytokines needs further investigation.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics committee of Center for Disease Prevention and Control of Shijiazhuang City.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional unpublished data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582–92.
2. Lee MH, Yang HI, Yuan Y, et al. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014;20:9270–80.
3. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119:1745–54.
4. Morgan TR, Ghany MG, Kim HY, et al. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology 2000;47:1675–9.
5. In this study, the size of the subgroups of individuals with HBV and/or HCV infections varied, which might have led to biases. More ideally, the samples should have been assessed by stratifying individuals into subgroups with individuals infected only by HCV and only by HBV. In addition, the correlation between interactions among the SNPs and the level of cytokines needs further investigation.

Contributors Q-JG designed the research, performed most of the experiments and drafted the manuscript; J-xX analysed the data and edited the paper; L-MW took the SNPs and the level of cytokines needs further investigation.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics committee of Center for Disease Prevention and Control of Shijiazhuang City.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional unpublished data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.